Laurus Labs said Sunday it has received tentative approval from the United States Food and Drug Administration for TLD, which is one of preferred first line regimen for the treatment of HIV.
The approval for Tenofovir/Lamivudine/Dolutegravir (TLD) 300/300/50mg fixed dose combination (FDC) was given under the US President's Emergency Plan for AIDS Relief, the company said in a release.
The TLD will be available in the generic form in low and middle income countries, it said.
The drug will be manufactured from the company's Unit 2 located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
Commenting on the USFDA approval, Laurus Labs CEO Satyanarayana Chava said, "It is a significant approval for Laurus Labs which has forayed into finished dosage forms recently. This product would demonstrate the company's capability to develop fixed dose combinations of ARVs (antiretroviral).
Laurus Labs has also received an Establishment Inspection Report from the USFDA for its Unit 6 located at APSEZ, Atchutapuram, on February 2, it said.
First Published: Feb 3, 2019 4:47 PM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
2024 Lok Sabha Elections | Will Amethi and Rae Bareli see the rise of Priyanka Gandhi as a dominant political figure
May 18, 2024 8:59 AM
Lok Sabha Election 2024: I.N.D.I.A. bloc to hold rally at Mumbai's BKC today
May 17, 2024 5:18 PM
In Ayodhya, voters talk of a promise fulfilled and yearning for development
May 17, 2024 2:10 PM
Fight of heavyweights in Sambalpur where farmers, weavers hold the key
May 17, 2024 12:25 PM